Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
THE FOLLOW-UP RESULTS OF LUX-VALVE PLUS TRINITY STUDY AND JENSCLIP CLINICAL STUDY PRESENTED AT EUROPCR 2025, SHOWING GOOD SAFETY AND PERFORMANCE

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated data in relation to the latest business and new product development of the Group.

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that recently, the 30-day clinical follow-up results of the global multicenter clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement (the "**TRINITY**"), as well as the one-year follow-up results of the JensClip transcatheter mitral valve repair ("**TMVr**") system, were officially released at the EuroPCR 2025 in Paris, France.

The 30-Day Global Follow-Up Results of LuX-Valve Plus TRINITY Study

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily evaluates the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and high surgical risk. The study enrolled 161 patients from 20 centers around the world, among which, 18 centers were from France, Germany, Spain, Denmark, and the UK.

The results of this clinical study showed:

(1) The device success rate was about 97%; and

(2) The average device operation time was 41.60±19.62 minutes, with the shortest device operating time being only 11 minutes.

The efficacy results showed:

(1) In terms of improvement in tricuspid regurgitation grade, 30-day outcomes demonstrated that 95.7% of patients had no above moderate regurgitation, while the Roll-in group outcomes demonstrated that 91.7% of patients had no above moderate regurgitation; and

(2) In terms of New York Heart Association cardiac function improvement, 30-day outcomes demonstrated that 84.1% of patients achieved postoperative cardiac function class I/II, while the Roll-in group outcomes demonstrated that 58.3% of patients achieved postoperative cardiac function class I/II; and

(3) In terms of quality of life, 30-day outcomes demonstrated that patients improved their Kansas City Cardiomyopathy Questionnaire scores, on average, by approximately 14 points, and the Roll-in group outcomes demonstrated that patients improved their Kansas City Cardiomyopathy Questionnaire scores, on average, by approximately 18 points.

The safety results showed:

Clinical Event Committee (CEC)-adjudicated Composite Events at 30-Day	**Full Analysis Set (FAS, N=149)**	**Roll-in (N=12)**
Cardiovascular mortality	2 (1.3%)	0 (0.0%)
Myocardial infarction	0 (0.0%)	0 (0.0%)
Strokes	1 (0.7%)	0 (0.0%)
New onset renal failure	0 (0.0%)	0 (0.0%)
Severe bleeding (includes fatal, life-threatening and extensive bleeding as defined by MVARC)	6 (4.0%)	0 (0.0%)
Non-selective tricuspid valve surgery/intervention post procedure	1 (0.7%)	1 (8.3%)
Major cardiac structural complications	3 (2.0%)	0 (0.0%)
Major access site and vascular complications	0 (0.0%)	0 (0.0%)
Device-related pulmonary embolism	0 (0.0%)	0 (0.0%)
New pacemaker implantation due to AV block	13 (8.7%)	1 (8.3%)
New pacemaker implantation due to AV block (Naive)	13 (11.9%)	1 (11.1%)

The overall CEC-adjudicated composite events rate at 30-Day of FAS group is 14.8%. The overall CEC-adjudicated composite events rate at 30-Day of FAS + Roll-in group is 14.9%.

The 30-day clinical follow-up results of the TRINITY study demonstrated good safety and performance of LuX-Valve Plus, with continued improvement in the quality of patient's life and a low rate of safety events. The broad range of application of LuX-Valve Plus is providing an excellent treatment option, particularly for patients of annular dilation with severe tricuspid regurgitation, who have limited choices among current clinical treatments. Collection of longer-term follow-up results and the U.S. Food and Drug Administration ("**FDA**") clinical study on LuX-Valve Plus have been in progress.

One-Year Follow-Up Results of JensClip

The study of JensClip TMVr system is a prospective, multicenter, single-arm clinical trial, which primarily evaluates the safety and efficacy of JensClip in application on patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk. The study enrolled 114 patients from 18 centers in China with an average age of 71 years old.

The results of this clinical study showed:

(1) The device operation success rate was about 95%; and

(2) The average device operation time was 67.53±43.89 minutes.

The efficacy results showed:

(1) In terms of improvement in mitral regurgitation grade, one-year follow-up results demonstrated that 96.3% of patients had no above moderate regurgitation;

(2) In terms of New York Heart Association cardiac function improvement, one-year follow-up results demonstrated that 93.5% of patients achieved a postoperative cardiac function class I/II; and

(3) In terms of quality of life, one-year follow-up results demonstrated that patients improved their Kansas City Cardiomyopathy Questionnaire scores, on average, by approximately 20 points with an average improvement of approximately 82 meters in the six-minute walking distance.

The safety results showed:

Major Adverse Events (N=114)	**At one year**
All-cause mortality	2 (1.8%)
Unplanned mitral valve intervention/surgery	6 (5.3%)
SLDA	0 (0.0%)
Stroke	2 (1.8%)
Renal failure	1 (0.9%)
Myocardium infarction	1 (0.9%)
Major bleeding	1 (0.9%)
Device related-technique failure	
Device related air embolism	0 (0.0%)
Device releasing/locking failure	1 (0.9%)
Clip related hemolysis	1 (0.9%)

JensClip is an innovative medical device designed for the treatment of severe mitral regurgitation with easy and reliable device operation. Its one-year follow-up results demonstrated outstanding performance with an all-cause mortality rate of only 1.8%, a low incidence of device-related complications, 96.3% of patients had no above moderate regurgitation. In addition, sustained improvement were demonstrated in indicators including New York Heart Association cardiac function, Kansas City Cardiomyopathy Questionnaire scores and six-minute walking distance.

The Company will continue to promote the application and commercialization of its products around the world.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus and JensClip successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, May 23, 2025

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.